Achilles Therapeutics Plc ADR [NASDAQ: ACHL] closed the trading session at $0.89 on 01/12/24. The day’s price range saw the stock hit a low of $0.8821, while the highest price level was $0.9003. The company report on December 18, 2023 at 7:00 AM that Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction.
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stocks have a year to date performance of -0.34 percent and weekly performance of 5.48 percent. The stock has been moved at -10.51 percent over the last six months. The stock has performed -1.56 percent around the most recent 30 days and changed 4.17 percent over the most recent 3-months.
If compared to the average trading volume of 144.27K shares, ACHL reached to a volume of 129326 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Achilles Therapeutics Plc ADR [ACHL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACHL shares is $6.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACHL stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Achilles Therapeutics Plc ADR shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 26, 2021.
The Average True Range (ATR) for Achilles Therapeutics Plc ADR is set at 0.05 The Price to Book ratio for the last quarter was 0.24, with the Price to Cash per share for the same quarter was set at 3.44.
ACHL stock trade performance evaluation
Achilles Therapeutics Plc ADR [ACHL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.48. With this latest performance, ACHL shares dropped by -1.56% in over the last four-week period, additionally sinking by -10.51% over the last 6 months – not to mention a drop of -25.55% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACHL stock in for the last two-week period is set at 52.31, with the RSI for the last a single of trading hit 51.66, and the three-weeks RSI is set at 52.04 for Achilles Therapeutics Plc ADR [ACHL]. The present Moving Average for the last 50 days of trading for this stock 0.8524, while it was recorded at 0.9109 for the last single week of trading, and 0.9178 for the last 200 days.
Achilles Therapeutics Plc ADR [ACHL]: An insightful look at the core fundamentals
Return on Total Capital for ACHL is now -28.04, given the latest momentum, and Return on Invested Capital for the company is -28.52. Return on Equity for this stock declined to -29.24, with Return on Assets sitting at -26.47. When it comes to the capital structure of this company, Achilles Therapeutics Plc ADR [ACHL] has a Total Debt to Total Equity ratio set at 4.35. Additionally, ACHL Total Debt to Total Capital is recorded at 4.17, with Total Debt to Total Assets ending up at 3.89. Long-Term Debt to Equity for the company is recorded at 2.23, with the Long-Term Debt to Total Capital now at 2.13.
Reflecting on the efficiency of the workforce at the company, Achilles Therapeutics Plc ADR [ACHL] managed to generate an average of -$293,934 per employee.Achilles Therapeutics Plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.55 and a Current Ratio set at 8.55.
Earnings per share (EPS) analysis for Achilles Therapeutics Plc ADR [ACHL] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACHL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Achilles Therapeutics Plc ADR go to 5.20%.
Achilles Therapeutics Plc ADR [ACHL]: Institutional Ownership
The top three institutional holders of ACHL stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in ACHL stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in ACHL stock with ownership which is approximately 5.8325%.
